“We are delighted to have established a companion diagnostics collaboration with Bayer, a global leader in the biopharmaceutical industry. Burning Rock is committed to the comprehensive development of companion diagnostics on a global scale, and we believe that through the integration of our resources and expertise in the field of cancer diagnosis and treatment, this collaboration will set a standard and high-quality model for the joint development of precision diagnostics. We aim to make a greater contribution to the advancement of precision oncology, providing more effective treatment options for patients and setting new benchmarks in the medical field,” said
About Burning Rock
Burning Rock is a biotechnology company that focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of 1) NGS-based therapy selection testing for late-stage cancer patients, 2) Global pharmaceutical services on biomarker detection and companion diagnostics developing, and 3) Early cancer detection.
For more information, please visit: us.brbiotech.com
Enquiries:
Contact: IR@brbiotech.com
![](https://ml.globenewswire.com/media/OWVkODE1ZmUtNDcxMi00ZmUyLTliZDUtNTE2MTU1YzVjZTM1LTEyMDY4MTI=/tiny/Burning-Rock-Biotech-Limited.png)
2024 GlobeNewswire, Inc., source